Advanced Cell Technology, Inc.  

(Public, OTCBB:ACTC)   Watch this stock  
Find more results for actc
0.0785
-0.0005 (-0.63%)
Jun 18 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.08 - 0.08
52 week 0.05 - 0.10
Open 0.08
Vol / Avg. 3.57M/12.47M
Mkt cap 187.45M
P/E     -
Div/yield     -
EPS -0.01
Shares 2.39B
Beta -1.84
Inst. own 0%
May 9, 2013
Q1 2013 Advanced Cell Technology, Inc. Earnings Conference Call
Apr 17, 2013
Advanced Cell Technology, Inc. at Alliance for Regenerative Medicine RegenMed Investor Day
  

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -7305.81% -6115.09%
Operating margin -6566.92% -4531.29%
EBITD margin - -4518.72%
Return on average assets -364.83% -240.91%
Return on average equity - -
Employees 36 -
Carbon Disclosure Rating - -

Address

#916, 1112 Montana Avenue
SANTA MONICA, CA 90403
United States - Map
+1-310-5760611 (Phone)
+1-310-5760662 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company�s emerging field of treatment called regenerative medicine or cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. It focuses on the development of effective methods to generate replacement cells from both human embryonic and adult stem cells. In September 2011, it received approval from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an SMD clinical trial in the United Kingdom.

Officers and directors

Gary H. Rabin Chairman of the Board and Chief Executive Officer
Age: 47
Robert P. Lanza M.D. Chief Scientific Officer
Age: 57
Michael T. Heffernan RPh Independent Director
Age: 48
Robert S. Langer Sc.D. Independent Director
Age: 65
Zohar Loshitzer Independent Director
Age: 55
Gregory D. Perry Independent Director
Age: 52
Alan C. Shapiro Ph.D. Independent Director
Age: 67